
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc has demonstrated strong financial performance, with a 59% increase in biopharma testing and services revenue, reaching $51 million in 2024, up from $32 million in 2023. The company achieved a gross margin of 27.1% in the fourth quarter of 2024, surpassing consensus expectations and reflecting a favorable customer mix alongside increased biopharma volume. Furthermore, the continuous growth in NeXT Dx and NeXT Personal test volumes, with a notable 53% rise, underscores the increasing demand for Personalis's genomic sequencing solutions and their successful partnerships in the market.
Bears say
Personalis Inc.'s financial outlook appears negative due to a significant decline in operating revenue, with 4Q24 revenue reported at $16.8 million, a 15% decrease year-over-year, which fell short of market expectations. Additionally, the company's revenue from biopharma, particularly from the ImmunoID NeXT platform, is expected to weaken in 2025 following the completion of enrollment in a key clinical study, suggesting challenges ahead in revenue generation. The risks of slower customer adoption of new products, increased competition, and declining income from the VA MVP program further contribute to a cautious outlook for the firm's financial performance.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares